JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell LymphomaMar 8, 2023
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular CarcinomaFeb 28, 2023
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual MeetingDec 12, 2022
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular CarcinomaJul 4, 2022